Cargando…

Challenges of using external data in clinical trials- an illustration in patients with COVID-19

BACKGROUND: To improve the efficiency of clinical trials, leveraging external data on control and/or treatment effects, which is almost always available, appears to be a promising approach. METHODS: We used data from the experimental arm of the Covidicus trial evaluating high-dose dexamethasone in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chevret, Sylvie, Timsit, Jean-François, Biard, Lucie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753019/
https://www.ncbi.nlm.nih.gov/pubmed/36522698
http://dx.doi.org/10.1186/s12874-022-01769-5
_version_ 1784850872328519680
author Chevret, Sylvie
Timsit, Jean-François
Biard, Lucie
author_facet Chevret, Sylvie
Timsit, Jean-François
Biard, Lucie
author_sort Chevret, Sylvie
collection PubMed
description BACKGROUND: To improve the efficiency of clinical trials, leveraging external data on control and/or treatment effects, which is almost always available, appears to be a promising approach. METHODS: We used data from the experimental arm of the Covidicus trial evaluating high-dose dexamethasone in severely ill and mechanically ventilated COVID-19 patients, using published data from the Recovery trial as external data, to estimate the 28-day mortality rate. Primary approaches to deal with external data were applied. RESULTS: Estimates ranged from 0.241 ignoring the external data up to 0.294 using hierarchical Bayesian models. Some evidence of differences in mortality rates between the Covidicus and Recovery trials were observed, with an matched adjusted odds ratio of death in the Covidicus arm of 0.41 compared to the Recovery arm. CONCLUSIONS: These indirect comparisons appear sensitive to the method used. None of those approaches appear robust enough to overcome randomized clinical trial data. TRIAL REGISTRATION: Covidicus Trial: NCT04344730, First Posted: 14/04/2020; Recovery trial: NCT04381936
format Online
Article
Text
id pubmed-9753019
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97530192022-12-15 Challenges of using external data in clinical trials- an illustration in patients with COVID-19 Chevret, Sylvie Timsit, Jean-François Biard, Lucie BMC Med Res Methodol Research BACKGROUND: To improve the efficiency of clinical trials, leveraging external data on control and/or treatment effects, which is almost always available, appears to be a promising approach. METHODS: We used data from the experimental arm of the Covidicus trial evaluating high-dose dexamethasone in severely ill and mechanically ventilated COVID-19 patients, using published data from the Recovery trial as external data, to estimate the 28-day mortality rate. Primary approaches to deal with external data were applied. RESULTS: Estimates ranged from 0.241 ignoring the external data up to 0.294 using hierarchical Bayesian models. Some evidence of differences in mortality rates between the Covidicus and Recovery trials were observed, with an matched adjusted odds ratio of death in the Covidicus arm of 0.41 compared to the Recovery arm. CONCLUSIONS: These indirect comparisons appear sensitive to the method used. None of those approaches appear robust enough to overcome randomized clinical trial data. TRIAL REGISTRATION: Covidicus Trial: NCT04344730, First Posted: 14/04/2020; Recovery trial: NCT04381936 BioMed Central 2022-12-15 /pmc/articles/PMC9753019/ /pubmed/36522698 http://dx.doi.org/10.1186/s12874-022-01769-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chevret, Sylvie
Timsit, Jean-François
Biard, Lucie
Challenges of using external data in clinical trials- an illustration in patients with COVID-19
title Challenges of using external data in clinical trials- an illustration in patients with COVID-19
title_full Challenges of using external data in clinical trials- an illustration in patients with COVID-19
title_fullStr Challenges of using external data in clinical trials- an illustration in patients with COVID-19
title_full_unstemmed Challenges of using external data in clinical trials- an illustration in patients with COVID-19
title_short Challenges of using external data in clinical trials- an illustration in patients with COVID-19
title_sort challenges of using external data in clinical trials- an illustration in patients with covid-19
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753019/
https://www.ncbi.nlm.nih.gov/pubmed/36522698
http://dx.doi.org/10.1186/s12874-022-01769-5
work_keys_str_mv AT chevretsylvie challengesofusingexternaldatainclinicaltrialsanillustrationinpatientswithcovid19
AT timsitjeanfrancois challengesofusingexternaldatainclinicaltrialsanillustrationinpatientswithcovid19
AT biardlucie challengesofusingexternaldatainclinicaltrialsanillustrationinpatientswithcovid19